VBI Vaccines Inc. (NASDAQ:VBIV) went up by 2.67% from its latest closing price compared to the recent 1-year high of $6.93. The company’s stock price has collected -0.32% of loss in the last five trading sessions. Press Release reported on 07/07/21 that VBI Vaccines Appoints Linda Bain to Board of Directors
Is It Worth Investing in VBI Vaccines Inc. (NASDAQ :VBIV) Right Now?
Plus, the 36-month beta value for VBIV is at 2.02. Opinions of the stock are interesting as 3 analysts out of 3 who provided ratings for VBI Vaccines Inc. declared the stock was a “buy,” while 0 rated the stock as “overweight,” 0 rated it as “hold,” and 0 as “sell.”
The average price from analysts is $8.00. VBIV currently public float of 197.16M and currently shorts hold a 13.83% ratio of that float. Today, the average trading volume of VBIV was 3.36M shares.
VBIV’s Market Performance
VBIV stocks went down by -0.32% for the week, with a monthly drop of -21.43% and a quarterly performance of 18.01%, while its annual performance rate touched -48.71%. The volatility ratio for the week stands at 5.23% while the volatility levels for the past 30 days are set at 5.87% for VBI Vaccines Inc.. The simple moving average for the period of the last 20 days is -9.72% for VBIV stocks with a simple moving average of -2.29% for the last 200 days.
Analysts’ Opinion of VBIV
Many brokerage firms have already submitted their reports for VBIV stocks, with Jefferies repeating the rating for VBIV by listing it as a “Buy.” The predicted price for VBIV in the upcoming period, according to Jefferies is $7 based on the research report published on February 25th of the current year 2021.
Raymond James, on the other hand, stated in their research note that they expect to see VBIV reach a price target of $9, previously predicting the price at $8. The rating they have provided for VBIV stocks is “Strong Buy” according to the report published on August 27th, 2020.
Oppenheimer gave a rating of “Outperform” to VBIV, setting the target price at $9 in the report published on January 16th of the previous year.
VBIV Trading at -8.88% from the 50-Day Moving Average
After a stumble in the market that brought VBIV to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -55.56% of loss for the given period.
Volatility was left at 5.87%, however, over the last 30 days, the volatility rate increased by 5.23%, as shares sank -19.37% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +10.79% upper at present.
During the last 5 trading sessions, VBIV fell by -0.32%, which changed the moving average for the period of 200-days by +12.82% in comparison to the 20-day moving average, which settled at $3.37. In addition, VBI Vaccines Inc. saw 12.00% in overturn over a single year, with a tendency to cut further gains.
Reports are indicating that there were more than several insider trading activities at VBIV starting from PERCEPTIVE ADVISORS LLC, who sale 646,257 shares at the price of $3.80 back on Jun 29. After this action, PERCEPTIVE ADVISORS LLC now owns 0 shares of VBI Vaccines Inc., valued at $2,455,777 using the latest closing price.
PERCEPTIVE ADVISORS LLC, the 10% Owner of VBI Vaccines Inc., sale 1,422,567 shares at $4.00 during a trade that took place back on Jun 09, which means that PERCEPTIVE ADVISORS LLC is holding 145,548 shares at $5,690,268 based on the most recent closing price.
Stock Fundamentals for VBIV
Current profitability levels for the company are sitting at:
- -4110.93 for the present operating margin
- -919.79 for the gross margin
The net margin for VBI Vaccines Inc. stands at -4357.21. The total capital return value is set at -29.66, while invested capital returns managed to touch -33.29. Equity return is now at value -34.50, with -28.00 for asset returns.
Based on VBI Vaccines Inc. (VBIV), the company’s capital structure generated 10.42 points at debt to equity in total, while total debt to capital is 9.44. Total debt to assets is 8.55, with long-term debt to equity ratio resting at 9.87. Finally, the long-term debt to capital ratio is 8.94.
When we switch over and look at the enterprise to sales, we see a ratio of 470.34, with the company’s debt to enterprise value settled at 0.04. The receivables turnover for the company is 0.26 and the total asset turnover is 0.01. The liquidity ratio also appears to be rather interesting for investors as it stands at 7.61.